Mannan adjuvants intranasally administered inactivated influenza virus in mice rendering low doses inductive of strong serum IgG and IgA in the lung

BMC Infectious Diseases

Volumn 15, Issue 1, 2015, Pages

  Proudfoot, Owen ^a   Esparon, Sandra ^a   Tang, Choon Kit ^b   Laurie, Karen ^c   Barr, Ian ^c   Pietersz, Geoffrey ^a,d,e  

^a BURNET INSTITUTE   (Australia)

^b OSAKA UNIVERSITY   (Japan)

^c WHO COLLABORATING CENTRE FOR REFERENCE AND RESEARCH ON INFLUENZA   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e MONASH UNIVERSITY   (Australia)

Author keywords

Adjuvant; Dose sparing; H1N1; IgA; Immunisation; Influenza; Intranasal; Mannan; Mucosal immunity; Vaccine

Indexed keywords

ADJUVANT; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; INFLUENZA VACCINE; MANNAN; IMMUNOLOGICAL ADJUVANT; VIRUS ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIGEN SPECIFICITY; ARTICLE; BLOOD SAMPLING; CELLULAR IMMUNITY; CONJUGATION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEMAGGLUTINATION INHIBITION; HEMAGGLUTINATION INHIBITION TEST; HUMORAL IMMUNITY; IMMUNITY; IMMUNIZATION; IMMUNOGLOBULIN BLOOD LEVEL; IN VITRO STUDY; INFLUENZA VACCINATION; INFLUENZA VIRUS A H1N1; LUNG LAVAGE; MOUSE; MUCOSAL IMMUNITY; NONHUMAN; REPEATED DRUG DOSE; RESPIRATORY SYSTEM; VACCINATION; VIRUS INACTIVATION; VIRUS STRAIN; VIRUS TRANSMISSION; VIRUS VIRULENCE; ANIMAL; ANTIBODY PRODUCTION; BAGG ALBINO MOUSE; BLOOD; DRUG EFFECTS; HUMAN; IMMUNOLOGY; INFLUENZA A VIRUS (H1N1); INTRANASAL DRUG ADMINISTRATION; LUNG; METABOLISM; ORTHOMYXOVIRIDAE INFECTIONS; PROCEDURES;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODIES, VIRAL; ANTIBODY FORMATION; FEMALE; HEMAGGLUTINATION INHIBITION TESTS; HUMANS; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; LUNG; MANNANS; MICE; MICE, INBRED BALB C; ORTHOMYXOVIRIDAE INFECTIONS; VACCINATION;

EID: 84928728310     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/s12879-015-0838-7     Document Type: Article

References (29)

1. Skowronski DM, De Serres G, Dickinson J, Petric M, Mak A, Fonseca K, et al. Component-specific effectiveness of trivalent influenza vaccine as monitored through a sentinel surveillance network in Canada, 2006-2007. J Infect Dis. 2009;199:168-79.
2. Belshe RB, Gruber WC. Safety, efficacy and effectiveness of cold-adapted, live, attenuated, trivalent, intranasal influenza vaccine in adults and children. Philos Trans R Soc Lond B Biol Sci. 2001;356:1947-51.
3. Gaglani MJ, Piedra PA, Herschler GB, Griffith ME, Kozinetz CA, Riggs MW, et al. Direct and total effectiveness of the intranasal, live-attenuated, trivalent cold-adapted influenza virus vaccine against the 2000-2001 influenza A(H1N1) and B epidemic in healthy children. Arch Pediatr Adolesc Med. 2004;158:65-73.
4. Kaplan BS, Webby RJ. The avian and mammalian host range of highly pathogenic avian H5N1 influenza. Virus Res. 2013;178:3-11.
5. Wu YL, Shen LW, Ding YP, Tanaka Y, Zhang W. Preliminary success in the characterization and management of a sudden breakout of a novel H7N9 influenza A virus. Int J Biol Sci. 2014;10:109-18.
6. Dhama K, Verma AK, Rajagunalan S, Deb R, Karthik K, Kapoor S, et al. Swine flu is back again: a review. Pak J Biol Sci. 2012;15:1001-9.
7. Karanikas V, Thynne G, Mitchell P, Ong CS, Gunawardana D, Blum R, et al. Mannan mucin-1 peptide immunization: influence of cyclophosphamide and the route of injection. J Immunother. 2001;24:172-83.
8. Apostolopoulos V, Pietersz GA, Tsibanis A, Tsikkinis A, Drakaki H, Loveland BE, et al. Pilot phase III immunotherapy study in early-stage breast cancer patients using oxidized mannan-MUC1 [ISRCTN71711835]. Breast Cancer Res. 2006;8:R27.
9. Loveland BE, Zhao A, White S, Gan H, Hamilton K, Xing PX, et al. Mannan-MUC1-pulsed dendritic cell immunotherapy: a phase I trial in patients with adenocarcinoma. Clin Cancer Res. 2006;12:869-77.
10. Stambas J, Pietersz G, McKenzie I, Cheers C. Oxidised mannan as a novel adjuvant inducing mucosal IgA production. Vaccine. 2002;20:1068-78.
11. Sheng KC, Kalkanidis M, Pouniotis DS, Esparon S, Tang CK, Apostolopoulos V, et al. Delivery of antigen using a novel mannosylated dendrimer potentiates immunogenicity in vitro and in vivo. Eur J Immunol. 2008;38:424-36.
12. Tang CK, Sheng KC, Esparon SE, Proudfoot O, Apostolopoulos V, Pietersz GA. Molecular basis of improved immunogenicity in DNA vaccination mediated by a mannan based carrier. Biomaterials. 2009;30:1389-400.
13. Apostolopoulos V, Pietersz GA, Loveland BE, Sandrin MS, McKenzie IF. Oxidative/reductive conjugation of mannan to antigen selects for T1 or T2 immune responses. Proc Natl Acad Sci U S A. 1995;92:10128-32.
14. Pietersz GA, Li W, Osinski C, Apostolopoulos V, McKenzie IF. Definition of MHC-restricted CTL epitopes from non-variable number of tandem repeat sequence of MUC1. Vaccine. 2000;18:2059-71.
15. Apostolopoulos V, Pietersz GA, Gordon S, Martinez-Pomares L, McKenzie IF. Aldehyde-mannan antigen complexes target the MHC class I antigen-presentation pathway. Eur J Immunol. 2000;30:1714-23.
16. Apostolopoulos V, Barnes N, Pietersz GA, McKenzie IF. Ex vivo targeting of the macrophage mannose receptor generates anti-tumor CTL responses. Vaccine. 2000;18:3174-84.
17. Sheng KC, Pouniotis DS, Wright MD, Tang CK, Lazoura E, Pietersz GA, et al. Mannan derivatives induce phenotypic and functional maturation of mouse dendritic cells. Immunology. 2006;118:372-83.
18. Rudin A, Johansson EL, Bergquist C, Holmgren J. Differential kinetics and distribution of antibodies in serum and nasal and vaginal secretions after nasal and oral vaccination of humans. Infect Immun. 1998;66:3390-6.
19. Donovan J, Brown P. Blood collection. In: Coligan JE, Bierer BE, Margulies DH, Shevach EM, Strober W, Coico R, editors. Current Protocols in Immunology. New York: John Wiley & Sons; 2006. Chapter 1:Unit 1.7.
20. WHO Collaborating Centers for Reference and Research on Influenza. Concepts and procedures for laboratory-based influenza surveillance. Washington D.C: U.S. Dept. of Health and Human Services; 1982.
21. Hobson D, Curry RL, Beare AS, Ward-Gardner A. The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses. J Hyg (Lond). 1972;70:767-77.
22. Fisman D, Pandemic Influenza Outbreak Research Modelling Team (Pan-InfORM). Modelling an influenza pandemic: A guide for the perplexed. CMAJ. 2009;181:171-3.
23. Ichinohe T, Tamura S, Kawaguchi A, Ninomiya A, Imai M, Itamura S, et al. Cross-protection against H5N1 influenza virus infection is afforded by intranasal inoculation with seasonal trivalent inactivated influenza vaccine. J Infect Dis. 2007;196:1313-20.
24. Belshe RB, Edwards KM, Vesikari T, Black SV, Walker RE, Hultquist M, et al. Live attenuated versus inactivated influenza vaccine in infants and young children. N Engl J Med. 2007;356:685-96.
25. Kjaerup RM, Dalgaard TS, Norup LR, Bergman IM, Sørensen P, Juul-Madsen HR. Adjuvant effects of mannose-binding lectin ligands on the immune response to infectious bronchitis vaccine in chickens with high or low serum mannose-binding lectin concentrations. Immunobiology. 2014;219:263-74.
26. Kelly H, Grant K. Interim analysis of pandemic influenza (H1N1) 2009 in Australia: surveillance trends, age of infection and effectiveness of seasonal vaccination. Euro Surveill. 2009;14:pii.19288.
27. Centers for Disease Control and Prevention (CDC). Surveillance for the 2009 pandemic influenza A (H1N1) virus and seasonal influenza viruses - New Zealand, 2009. MMWR Morb Mortal Wkly Rep. 2009;58:918-21.
28. Centers for Disease Control and Prevention (CDC). Swine influenza A (H1N1) infection in two children-Southern California, March-April 2009. MMWR Morb Mortal Wkly Rep. 2009;58:400-2.≥
29. UK Government: Swine flu - what the government is doing. www.rsphealthcare.com/ 2009, last accessed May 2013.